A microfluidic method called MarrowCellDLD for retrieving fragile bone marrow-derived cells without the need for labeling – Scientific Reports
Bone marrow-derived cells play a crucial role in various medical applications, including stem cell therapy and regenerative medicine. However, isolating these fragile cells from bone marrow samples can be challenging and often requires the use of labeling techniques that may alter their properties. In a recent study published in Scientific Reports, researchers have introduced a novel microfluidic method called MarrowCellDLD, which allows for the retrieval of bone marrow-derived cells without the need for labeling.
Traditionally, the isolation of bone marrow-derived cells involves complex and time-consuming procedures, such as density gradient centrifugation or magnetic-activated cell sorting (MACS). These methods often require the use of fluorescent labels or magnetic beads to specifically target and separate the desired cells from the heterogeneous bone marrow sample. However, these labeling techniques can affect the viability and functionality of the isolated cells, limiting their potential applications.
The MarrowCellDLD method overcomes these limitations by utilizing a microfluidic device that exploits the unique physical properties of bone marrow-derived cells. The device consists of a series of microchannels with precisely designed dimensions and structures. As the bone marrow sample flows through these channels, the cells experience different forces based on their size and deformability.
The key principle behind MarrowCellDLD is the deterministic lateral displacement (DLD) effect, which allows for the separation of cells based on their size. The microchannels in the device are engineered in such a way that larger cells are displaced laterally while smaller cells continue to flow straight. This differential displacement enables the isolation of specific cell populations without the need for labeling.
The researchers tested the efficacy of MarrowCellDLD using both simulated samples and real bone marrow samples from mice. They successfully demonstrated the efficient retrieval of bone marrow-derived cells, including mesenchymal stem cells and hematopoietic stem cells, without any significant loss of cell viability or functionality. The isolated cells maintained their characteristic properties and could be further cultured and expanded for various applications.
One of the major advantages of MarrowCellDLD is its simplicity and rapidity compared to traditional methods. The entire process can be completed within a few minutes, making it highly suitable for point-of-care applications or in situations where time is critical. Additionally, the method does not require any specialized equipment or expensive reagents, making it cost-effective and accessible to a wider range of researchers and clinicians.
The MarrowCellDLD method holds great promise for advancing bone marrow-derived cell research and applications. Its label-free approach ensures the preservation of cell integrity and functionality, allowing for more accurate and reliable results. Furthermore, the simplicity and speed of the method make it highly attractive for clinical translation, potentially revolutionizing the field of bone marrow-based therapies.
In conclusion, the introduction of MarrowCellDLD as a microfluidic method for retrieving fragile bone marrow-derived cells without the need for labeling represents a significant breakthrough in the field. This innovative approach offers a simple, rapid, and cost-effective solution for isolating these valuable cells, opening up new possibilities for their use in various medical applications. Further research and development of MarrowCellDLD could lead to advancements in stem cell therapy, regenerative medicine, and other fields where bone marrow-derived cells play a crucial role.